An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment / Gentile, M; Shanafelt, Td; Mauro, Fr; Reda, G; Rossi, D; Laurenti, L; Del Principe, Mi; Cutrona, G; Angeletti, I; Coscia, M; Herishanu, Y; Chiarenza, A; Molica, S; Ciolli, S; Goldschmidt, N; Angrilli, F; Giordano, A; Rago, A; Bairey, O; Tripepi, G; Chaffee, Kg; Sameer, Pa; Vigna, E; Zirlik, K; Shvidel, L; Innocenti, I; Recchia, Ag; Di Raimondo, F; Del Poeta, G; Cortelezzi, A; Neri, A; Ferrarini, M; Gaidano, G; Kay, Ne; Polliack, A; Foà, R; Morabito, F.. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - STAMPA. - (2018). [10.1111/ejh.13149]
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment.
Mauro FRSecondo
;Foà R;
2018
Abstract
An international collaboration has led to the development of a comprehensive tool [CLL-IPI international prognostic index for CLL] for the predicting of overall survival (OS) in chronic lymphocytic leukemia (CLL).1 CLL-IPI was based on data collected from 3500 CLL patients and was based on the following parameters: TP53 deletion and/or mutation, IGHV mutational status, β2-microglobulin plasma levels, clinical stage, and age. CLL-IPI provides the means to stratify CLL patients in the daily clinical practice (Supplementary Table 1).1 Although validated for OS2-4 and time to first treatment (TTFT),5 the predictive value of CLL-IPI on progression-free survival (PFS) has until now only been demonstrated in a single study on patients treated with chlorambucil (CLB), as monotherapy, or in combination with obinutuzumab or rituximab, as a first-line approach (CLL11 study),6 and presented as a poster at the annual meeting of the American Society of Hematology (ASH) in 2016. This article is protected by copyright. All rights reserved.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
